Author Correction: Targeting pro-inflammatory T cells as a novel therapeutic approach to potentially resolve atherosclerosis in humans

Fan Lin, Junwei Liu, Wei Hu, Zexin Chen, Jie Lan, Tongtong Zhang, Yang Zhang, Xianpeng Wu, Zhiwei Zhong, Danyang Zhang, Jinlong Zhang, Rui Qin, Hui Chen, Yunfeng Zong, Jianming Zhang, Bing Chen, Jun Jiang, Jifang Cheng, Jingyi Zhou, Zhiwei Gao, Zhenjie Liu, Ying Chai, Junqiang Fan, Pin Wu, Yinxuan Chen, Yuefeng Zhu, Kai Wang, Ying Yuan, Pintong Huang, Ying Zhang, Huiqin Feng, Kaichen Song, Xun Zeng, Wei Zhu, Xinyang Hu, Weiwei Yin, Wei Chen, Jianan WangCell 2024 · DOI · OpenAlex

This document serves as a formal Author Correction for the study titled "Targeting pro-inflammatory T cells as a novel therapeutic approach to potentially resolve atherosclerosis in humans," originally published in Cell Research in March 2024. While the core findings of the study remain unchanged, this correction provides essential technical clarifications to ensure the scientific record is accurate and reproducible.

This formal correction ensures the scientific record remains accurate and up-to-date.

Context and Significance

The original research investigated atherosclerosis—the chronic inflammatory buildup of plaque in arterial walls—and explored whether targeting pro-inflammatory T cells could offer a viable therapeutic strategy. Specifically, the authors focused on the PD-1/PD-L1 pathway. In high-stakes immunology, precise terminology and data labeling are paramount for understanding cell-to-cell interactions and cytokine signaling. This correction addresses several errata that appeared in the initial publication.

Technical and Methodological Clarifications

1. Micro-pipette Adhesion Assay

A key correction involves the description of the biophysical techniques used. The original text incorrectly referred to a "micro-peptide" assay. The authors have clarified that they utilized a micro-pipette adhesion assay. This sophisticated method is used to qualitatively and quantitatively determine the in-situ interaction between primary CD64+ cells and PD-1+ T cells. This assay was critical for evaluating how Nivolumab (an anti-PD-1 monoclonal antibody) modulates these interactions.

2. Immunological Nomenclature: FcγR-binding

The authors have updated the terminology from "Fc-binding" to "FcγR-binding" (and "non-FcγR-binding"). This distinction is vital for immunologists, as Fcγ receptors (FcγR) are the specific receptors for the Fc region of IgG antibodies. This clarification defines the exact mechanism by which therapeutic antibodies interact with immune cells in the context of atherosclerosis.

3. Cell Surface Marker Accuracy

In Figure 6a, a label was corrected from "CD45–" to "CD45+" for PD-L1 expressing cells. Since CD45 is a pan-leukocyte marker, this correction accurately identifies the cells as being of hematopoietic (immune) origin, which is central to the study's focus on immune-mediated inflammation.

Data Visualization and Reference Updates

The correction also addresses several visual and citation errors:

  • Cytokine Concentrations: The Y-axis labels for IL-2 and IFN-γ in Figure 4g were corrected to accurately reflect concentrations in pg/mL. These pro-inflammatory cytokines are key indicators of T-cell activity.
  • Heatmap Alignment: Cluster frequency annotations in Figure 3a were re-ordered to correctly match the corresponding data rows.
  • Literature Integrity: Reference 53 was updated from a bioRxiv preprint to its final peer-reviewed version in PLoS ONE (2021), ensuring the foundational work on Rora expression in CD4+ T cells is properly cited.

Conclusion

The authors emphasize that these technical corrections do not alter the results or the final conclusions of the research. The primary discovery—that targeting specific pro-inflammatory T cells can potentially resolve atherosclerosis—remains robust and supported by the corrected data. These updates ensure that researchers building upon this work have the most accurate technical framework possible.

Summary updated

BibTeX
@inproceedings{lin2024author,
  author = {Fan Lin and Junwei Liu and Wei Hu and Zexin Chen and Jie Lan and Tongtong Zhang and Yang Zhang and Xianpeng Wu and Zhiwei Zhong and Danyang Zhang and Jinlong Zhang and Rui Qin and Hui Chen and Yunfeng Zong and Jianming Zhang and Bing Chen and Jun Jiang and Jifang Cheng and Jingyi Zhou and Zhiwei Gao and Zhenjie Liu and Ying Chai and Junqiang Fan and Pin Wu and Yinxuan Chen and Yuefeng Zhu and Kai Wang and Ying Yuan and Pintong Huang and Ying Zhang and Huiqin Feng and Kaichen Song and Xun Zeng and Wei Zhu and Xinyang Hu and Weiwei Yin and Wei Chen and Jianan Wang},
  title = {{Author Correction: Targeting pro-inflammatory T cells as a novel therapeutic approach to potentially resolve atherosclerosis in humans}},
  booktitle = {Cell},
  year = {2024},
  doi = {10.1038/s41422-024-01003-5},
}
Figure